COLUMBUS, Ohio, Jan. 4, 2021 /PRNewswire/ --Forge Biologics Inc., a gene therapy manufacturing and development company, today announced that the company has received FDA clearance of the Investigational New Drug (IND) to initiate a Phase 1/2 clinical trial evaluating its novel, first-in-human AAV gene therapy, FBX-101, for patients with Krabbe disease. FBX-101 is the company's first therapeutic program to receive an IND which also received Institutional Biosafety Committee (IBC) and Institutional Review Board (IRB) approvals required prior to any patient enrollment. This marks a major step forward in building out the company's hybrid model as a gene therapy manufacturing and development engine.
Krabbe disease is a rare and fatal pediatric leukodystrophy affecting about 1-2.6 in 100,000 people in the United States. Patients are born with mutations in the galactosylceramidase(GALC) gene, which encodes an enzyme that helps break down lipid molecules inside cells. This results in the toxic buildup of psychosine, a lipid molecule that can't be degraded in cells, particularly in cells in the brain and peripheral nerves, and leads to toxic levels that cause cell death and myelin loss. The disease initially presents as physical delays in development, muscle tightness and irritability, and rapidly advances to difficulty swallowing and breathing, loss of vision and hearing, and increasing cognitive degeneration. Early onset, or "Infantile", Krabbe disease cases usually results in death by age 2-4 years, while later onset or "Late Infantile" cases have a more variable course of progressive decline. There is currently no approved treatment for either form of Krabbe disease.
FBX-101 is an adeno-associated viral (AAV) gene therapy administered after hematopoietic stem cell transplant (HSCT), that delivers a functioning copy of the GALC gene, the enzyme needed to prevent the buildup of psychosine in myelinated cells of both the central and peripheral nervous system. FBX-101 has been shown to correct the central and peripheral myelination deficits, significantly improve the behavioral impairments associated with Krabbe disease in animal models, and drastically improve the lifespan of treated animals. The use of transplant and intravenous AAV gene therapy infusion has the potential to overcome some of the immunological safety challenges of traditional AAV gene therapies.
"The ground-breaking treatment approach using HSCT and AAV gene therapy, initially developed by Dr. Escolar, has safely demonstrated superior benefits in preclinical animal studies of Krabbe disease than either treatment method alone," said Timothy J. Miller, Ph.D., Forge's CEO, President, and Co-Founder. "We are grateful for the FDA's engaged review and allowance of the IND, and look forward to enrolling patients very soon."
FBX-101 is the culmination of nearly 20 years of Krabbe disease research, led by Maria Escolar, M.D., M.S., Chief Medical Officer at Forge Biologics and the pioneer for evaluating the natural history and new treatment approaches for patients with Krabbe disease. "This combination approach is extremely exciting because the preclinical data demonstrate significant correction of survival, behavior and neuromuscular function in animal models compared to either transplant or AAV treatment alone. This is a significant milestone for Krabbe disease families suffering from this deadly disease," said Dr. Escolar.
The initiation of the RESKUE trial in Forge's gene therapy pipeline continues Forge's momentum within the biotechnology industry in Columbus, Ohio, bringing positive impact to both Ohio and the global rare disease community.
Patients and families can learn more about clinical trials for FBX-101 by visiting https://www.forgebiologics.com/science/#krabbe.
About Krabbe diseaseKrabbe disease is a rare, pediatric leukodystrophy affecting about 1-2.6 in 100,000 people in the U.S. and is inherited in an autosomal recessive manner. Krabbe disease is caused by loss-of-function mutations in the galactosylceramidase (GALC) gene, a lysosomal enzyme responsible for the breakdown of certain types of lipids such as psychosine. Without functional GALC, psychosine accumulates to toxic levels in cells. The psychosine toxicity is most severe in the myelin cells surrounding the nerves in the brain and in the peripheral nervous system, eventually leading to the death of these cells. The disease initially manifests as physical delays in development, muscle weakness and irritability and advances rapidly to difficulty swallowing, breathing problems, cognitive, vision and hearing loss. Early onset or "Infantile", Krabbe disease cases usually results in death by age 2-4 years, while later onset or "Late Infantile" cases have a more variable course of progressive decline. There is currently no approved treatment for Krabbe disease.
About FBX-101Forge is developing FBX-101 to treat patients with infantile Krabbe disease. FBX-101 is an adeno-associated viral (AAV) gene therapy that is delivered after a hematopoietic stem cell transplant. FBX-101 delivers a functional copy of the GALC gene to cells in both the central and peripheral nervous system. FBX-101 has been shown to functionally correct the central and peripheral neuropathy and correct the behavioral impairments associated with Krabbe disease in animal models, and to drastically improve the lifespan of treated animals. This approach has the potential to overcome some of the immunological safety challenges observed in traditional AAV gene therapies.
About Forge BiologicsForge Biologics is a hybrid gene therapy contract manufacturing and therapeutic development company. Forge's mission is to enable access to life changing gene therapies and help bring them from idea into reality. Forge has a 175,000 ft2 facility in Columbus, Ohio, "The Hearth", to serve as their headquarters. The Hearth is the home of a custom-designed cGMP facility dedicated to AAV viral vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing.By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.
For more information, please visit https://www.forgebiologics.com.
Patient, Pediatrician, Genetic Counselors & Family Inquiries
Dr. Maria EscolarChief Medical OfficerForge Biologics Inc.[emailprotected]
Media Inquiries:
Dan SalvoDirector of Communications and Community DevelopmentForge Biologics Inc.[emailprotected]
Investor Relations and Business Development
Christina PerryVice President, Finance and OperationsForge Biologics Inc.[emailprotected]
SOURCE Forge Biologics
Here is the original post:
Forge Biologics Announces FDA Clearance of Investigational New Drug Application for Phase 1/2 Clinical Trial (RESKUE) of FBX-101 Gene Therapy for...
- Making Blood Stem Cells on a Microchip: Academic Minute - December 27th, 2022
- Novel detection of stem cell niche within the stroma of limbus in the rabbit during postnatal development | Scientific Reports - Nature.com - August 14th, 2022
- Why Nebraska's U.S. Airmen have filed a lawsuit refusing the COVID-19 vaccine - KETV Omaha - July 27th, 2022
- Hepatic stellate cells in liver development, regeneration, and cancer - July 11th, 2022
- Fasting triggers stem cell regeneration of damaged, old immune system ... - June 13th, 2022
- Columbus man to be one of first to receive transplant via new OhioHealth program - 10TV - April 19th, 2022
- Grayson authorizes more than $1 million for ongoing and new equine research in 2022 - EQUUS Magazine - March 25th, 2022
- Cancer stem cells in glioblastoma - January 20th, 2022
- First-responder cells after heart attack prompt ... - January 20th, 2022
- New clinical trials from University Hospitals Seidman Cancer Center to begin with human protein following successful on-site approach to producing and... - December 24th, 2021
- Riverside Biologics Health Review: At Home "Stem Cells ... - December 24th, 2021
- China-bound Graduate Focused on Global Goals - University of Mary Washington - December 10th, 2021
- Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia -... - December 10th, 2021
- Fruit Cells, Space Bread, and Cultured Meat Cartridges: Deep Space Food Challenge Announces Phase 1 Winners - The Spoon - October 28th, 2021
- Fungi foray: Wild mushrooms are a key part of food chain - Farm and Dairy - August 5th, 2021
- AgeX Therapeutics Inc. (NYSE:AGE) stock surged in the premarket trading session; heres why - Market Globalist - May 13th, 2021
- University Hospitals treats first cancer patient in Ohio with "game changing" CAR T therapy - News 5 Cleveland - May 13th, 2021
- Weekly line: What the new coronavirus variants mean for vaccines, transmission, and more - The Daily Briefing - January 20th, 2021
- The Rise of Steve Sarkisian ... And the Decline of the Man Who Got Him Here - Sports Illustrated - January 9th, 2021
- Raleigh man delivers stem cells to patients around the world - WRAL.com - November 28th, 2020
- A real life Superman celebrates 5 years of survival from one of the deadliest cancers - Newswise - November 28th, 2020
- The Museum That Fell From the Sky | History - Air & Space Magazine - November 28th, 2020
- A Detroit Lions VP tries to avoid wasting her daughter from uncommon illness - The Shepherd of the Hills Gazette - November 28th, 2020
- US biotechnology company races to get its COVID-19 therapeutic approved for access, which has previously shown positive results in severely ill... - November 5th, 2020
- STEM CELLS - Regenerative Medicine Institute of Ohio - October 18th, 2020
- FDA Grants Orphan Drug Designation to Novel Bcl-2 inhibitor in CLL - Targeted Oncology - September 9th, 2020
- Breastfeeding 'even better than previously thought' - The Irish News - The Irish News - June 29th, 2020
- Regenerative Therapy Options for Horses With Osteoarthritis - TheHorse.com - June 12th, 2020
- Why Do Some People Get Sick All the Time, While Others Stay in Freakishly Good Health? - Discover Magazine - June 12th, 2020
- How safe are Ohio summer fun activities amid the coronavirus threat? The Wake Up for Friday, May 29, 2020 - cleveland.com - May 31st, 2020
- Kenneth Wallace Promoted to Full Professor at Clarkson University - Clarkson University News - May 31st, 2020
- ODDS AND ENDS: Melonheads and other offbeat offerings - Toronto Sun - May 31st, 2020
- OHIO researchers win grant to study treatment for possible fatal complications of COVID-19 - Huntington Herald Dispatch - May 8th, 2020
- Coronavirus Today: We're starting to reopen - Los Angeles Times - May 8th, 2020
- COMMENTARY || Pseudoscience and COVID-19we've had enough already - Folio - University of Alberta - May 3rd, 2020
- This Week in Green Tech: STEM Lessons, Solar Power and the Coronavirus, and More - ENGINEERING.com - May 3rd, 2020
- AskBio Announces First Patient Dosed in Phase 1 Trial Using AAV Gene Therapy for Congestive Heart Failure - BioSpace - February 7th, 2020
- Tune in Tonight: Oscar-nominated The Cave debuts on National Geographic - St. Augustine Record - January 25th, 2020
- Best Stem Cell Therapy Treatment in Cincinnati, Ohio ... - November 28th, 2019
- Time to Try Again: Gene-Based Therapy for Neurodegeneration - Alzforum - November 28th, 2019
- NIA Mourns the Loss of Dr. Huber Warner - National Institute on Aging - November 13th, 2019
- Research Roundup: Genomic Dark Matter Mutation and More - BioSpace - October 23rd, 2019
- Stem Cell Treatment Lima | Orthopaedic Institute of Ohio - September 10th, 2019
- Regenerative Therapy in Northeast Ohio | Ohio Therapy Centers - September 9th, 2019
- Stem cell therapy now available in central Ohio! - May 30th, 2019
- Stem Cell Therapy Clinic in Cleveland, Ohio - March 26th, 2019
- Massages & Treatments | Day Spa on Lake Erie in Ohio | The ... - March 10th, 2019
- *NEW* Regenerative Stem Cell Therapy | Ohio Therapy Centers - December 7th, 2018
- Stem Cell Therapy | Ohio Stem Cell - November 5th, 2018
- Ohio Stem Cell Treatment Center of Cleveland (Beachwood ... - November 3rd, 2018
- Conjoined twins - Wikipedia - September 20th, 2018
- Government website steers patients to unproven medical treatments - MyAJC - September 2nd, 2017
- Modern Health & Wellness of Lima institutes regenerative stem cell therapy - Lima Ohio - September 2nd, 2017
- Salk faces 'daunting' need for money despite big success with ... - The San Diego Union-Tribune - August 26th, 2017
- 'Nanotransfection' Turns Animal Skin into Blood Vessels and Brain ... - Medical Device and Diagnostics Industry - August 26th, 2017
- This Chip Uses Electricity to Reprogram Cells for Healing - Singularity Hub - August 25th, 2017
- This year's freshman class at Misericordia University is third largest in school history - The Dallas Post - August 25th, 2017
- Nanochip Could Heal Injuries or Regrow Organs with One Touch - NewsFactor Network - August 18th, 2017
- Wild new microchip tech could grow brain cells on your skin - CNET - August 8th, 2017
- Researchers explore possible alternative to knee replacement - Scope (blog) - August 5th, 2017
- Jackson Twp.'s Emmie Wanzer loves her new wheelchair swing provided by Wishes Can Happen Wanzer - Canton Repository - July 4th, 2017
- Scientists Discover That Fasting Triggers Stem Cell ... - November 23rd, 2016
- Stem-Cells | The Institute for Applied & Professional Ethics - November 18th, 2016
- Stem Cell Transplant Program - Cleveland, Ohio - October 17th, 2016
- Update: Ohio Stem Cell Study Recruiting People with MS ... - October 17th, 2016
- National Center For Regenerative Medicine - October 17th, 2016
- Stem-cell niche - Wikipedia, the free encyclopedia - October 19th, 2015
- Alex Potoczak of Ohio Praises Umbilical Stem Cell Research ... - July 2nd, 2015
- Dr. Foglietti | Ohio Stem Cell Treatment Center of Cleveland - April 27th, 2015
- Taubman Institute Receives $3 Million Wexner Gift to Support Emerging Physician-Researchers - April 3rd, 2015
- Morgan's Fund Launches Necrotizing Enterocolitis (NEC) Podcast Series: Premiere Features Dr. Gail Besner - March 24th, 2015
- Ohio Stem Cell Knee Arthritis Treatment-Regenexx - February 23rd, 2015
- We Were Promised Space Lasers: The State of the Union's Biggest Fibs - January 21st, 2015
- We Were Promised Space Lasers: State of the Union's Biggest Fibs - January 20th, 2015
- We Were Promised Space Lasers: The State of the Union's Big Fibs - January 17th, 2015
- 'Unprecedented': Drug May Help Heal Damaged Spines - December 4th, 2014
- New DNA discovery could lead to chromosome therapies in the future - November 19th, 2014
- Tiny Stomachs Grown in the Lab - October 31st, 2014
- Stem Cells Used to Grow Mini-Stomachs Seeking Treatments - October 30th, 2014
- Scientists build 'mini-stomachs' in lab - October 30th, 2014